Haematology

CAR T-cells attacking a cancer cell
#CAR-T #Haematology #Myeloma #Oncology #Phase I trial #Poseida Therapeutics #Roche

Patients show 91% response to allogeneic CAR-T therapy

Investigators saw a 91% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma (RRMM) following treatment with allogeneic CAR-T therapy P-BCMA-ALLO1 and lymphodepletion. The interim data from an ongoing Phase I trial in patients who have previously received three or more prior lines of therapy… Read More

#Cancer Research #News

#Cancer research #Cancer therapeutics #Haematology #Oncology

New DDW Highlights vodcast: 31 July 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   There have been some interesting… Read More

#News

#Cancer research #Cancer therapeutics #Haematology #Oncology

New DDW Highlights vodcast: 23 July 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   The chosen news stories this… Read More

#News

#Cancer research #Cancer therapeutics #Haematology #Oncology

New DDW Highlights podcast: 22 July 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The chosen news stories this week all feature therapies that could have significant… Read More

#News

#Cancer research #Cancer therapeutics #Haematology #Oncology

This week in drug discovery (15-19 July) 

News round-up for 15-19 July by DDW Senior Digital Content Editor Diana Spencer. The chosen news stories this week all feature therapies that could have significant impact on the future treatment of cancer, particularly haematological malignancies, but also solid tumours. The top stories:… Read More

#News

#allogeneic cell therapies #Blood cancer #CAR-T #Cell and gene therapy #Cell therapy #Haematology

New DDW Highlights podcast: 24 June 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It’s been another busy week in the world of cell therapy, with the first… Read More

#News

#allogeneic cell therapies #Blood cancer #CAR-T #Cell and gene therapy #Cell therapy #Haematology

This week in drug discovery (17-21 June) 

News round-up for 17-21 June by DDW Senior Digital Content Editor Diana Spencer. It’s been another busy week in the world of cell therapy, with the first use of CAR-T therapy for stiff-person syndrome, a study debunking the risk of secondary cancers from CAR-T and a number of… Read More

#News

Blood cancer
#Antibodies #Blood cancer #CAR-T #Cell therapy #Clinical trials #Events #Haematology

EHA2024: Industry shares latest drug research in blood cancers

A number of key findings in haematological malignancies were revealed at this year’s European Hematology Association (EHA) Congress, which was held in Madrid, Spain 13-16 June. Ibrutinib and talquetamab, Johnson & Johnson Johnson & Johnson shared clinical trial results for its drug candidates Talvey (talquetamab) and… Read More

#Cancer Research #News #Trending News

Bispecific antibodies
#AbbVie #ASCO #Bispecific Antibodies #Follicular lymphoma #Genmab #Haematology #Oncology

95% response to bispecific antibody in follicular lymphoma

Previously untreated follicular lymphoma (FL) patients who received epcoritamab with rituximab-lenalidomide (R2) had a 95% overall response rate (ORR), according to preliminary trial data. The results of two ongoing Phase I/II clinical trials evaluating cancer immunotherapy epcoritamab, a T-cell engaging bispecific antibody, were shared at… Read More

#Cancer Research #News #Trending News

Blood cells
#Biotechnology #Collaboration #Funding #Haematology #Hemostatics

Validating a revolutionary therapy against lethal haemorrhage 

A public-private consortium formed by the biotech Hemostatics, based at the Barcelona Science Park, the Clínica Universidad de Navarra (CUN) and the Institute of Chemical Research of Catalonia (ICIQ), has received €2.5 million from the Spanish Research Agency (AEI), under the call for grants for Public-Private Collaboration Projects, to… Read More

#News

Cytokine release syndrome
#Cancer treatment #Clinical trials #Haematology #Immunotherapy #Institute of Cancer Research #Poolbeg Pharma

Treatment potential for immunotherapy-induced CRS

Poolbeg Pharma, a biopharmaceutical company focused on the development and commercialisation of medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced cytokine release syndrome (CRS).   POLB 001 demonstrated efficacy in reducing… Read More

#Cancer Research #News

T cell attacking cancer cell
#AbbVie #CAR-T #Collaboration #Haematology #In vivo #Umoja Biopharma

Collaboration boosts development of novel in-situ CAR-T cell therapies

AbbVie and Umoja Biopharma have entered into two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology. The first agreement provides AbbVie an exclusive option to license Umoja's CD19 directed in-situ generated CAR-T cell therapy candidates. This includes UB-VV111, Umoja's lead clinical programme… Read More

#Business & Investment #News

#American Society of Hematology #Blood cancer #Cancer research #CAR-T #Haematology #Oncology

New DDW Highlights podcast for 19 December 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Our news highlights this week focus on haematology, thanks in part to a number… Read More

#News

#American Society of Hematology #Blood cancer #Cancer research #CAR-T #Haematology #Oncology

This week in drug discovery (11-15 December) 

News round-up for 11-15 December by DDW Digital Content Editor Diana Spencer. Our news highlights this week focus on haematology, thanks in part to a number of key announcements at the 65th American Society for Hematology meeting (ASH) Annual Meeting, including real-world evidence on the use of… Read More

#News

Myeloma cells
#Blood cancer #CellCentric #Haematology #Myeloma #Oncology #Phase I trial

New class of drug shows promise in last line multiple myeloma

Data presented at the American Society for Hematology meeting (ASH) show a 70% response rate in last line multiple myeloma patients treated with CellCentric’s inobrodib in combination with pomalidomide (pom) and dexamethasone (dex). Inobrodib is the first in a new class of drug, which disrupts the… Read More

#Cancer Research #News

CAR-T therapy
#Blood cancer #CAR-T #Haematology #Kite Pharma #Oncology #Real world data

Real-world evidence supports use of CAR-T therapies in blood cancers

Real-world evidence from the French DESCAR-T registry has shown an overall response rate (ORR) of 76.9% and complete response rate (CR) of 57.7% in large B-cell lymphoma (LBCL) patients treated with axicabtagene ciloleucel (Yescarta). Axicabtagene ciloleucel was also associated with less than 5% grade ≥3 cytokine… Read More

#Cancer Research #News #Trending News